Cohance Lifesciences , a prominent player in the pharmaceutical sector, witnessed a significant change in its shareholding pattern as one of its promoters, Jusmiral Holdings Limited, sold a substantial portion of its stake on September 18, 2025.

Key Details of the Transaction

• Shares Sold: 3,41,48,000
• Transaction Date: September 18, 2025
• Mode of Sale: On-market transaction through the National Stock Exchange of India Limited
• Sale Proceeds: ₹3093.81 crore

Impact on Shareholding

The sale has resulted in a notable reduction in Jusmiral Holdings' stake in Cohance Lifesciences:

Purpose of the Sale

According to the disclosure made by Jusmiral Holdings Limited, the proceeds from this share sale will be primarily utilized for:

• Part payment of borrowings under a Notes Purchase Agreement
• This agreement was previously disclosed on May 9, 2025

Regulatory Compliance

The transaction and subsequent disclosure were made in compliance with:

1. SEBI's Prohibition of Insider Trading Regulations, 2015
2. Regulation 7(2) read with Regulation 6(2) – Continual Disclosure

Jusmiral Holdings Limited, based in Cyprus, promptly informed Cohance Lifesciences of the transaction. The company, in turn, notified both the BSE Limited and the National Stock Exchange of India Limited, adhering to regulatory requirements.

Company Background

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited, operates in the pharmaceutical sector. The company's shares are traded on the National Stock Exchange of India Limited and the BSE Limited.

This significant reduction in promoter holding may attract investor attention and could potentially impact the stock's trading patterns in the coming days.

Cohance Lifesciences , a Hyderabad-based contract development and manufacturing organisation, witnessed a significant market event as 3.39 crore shares, representing 8.9% of the company's equity, changed hands through block deals. The transaction, valued at ₹3,073.00 crore, triggered a sharp decline in the company's stock price, which fell over 6% in early trading.

Block Deal Details

Jusmiral Holdings, which held a 33.34% stake in Cohance Lifesciences at the end of the June quarter, executed the sale of its 8.9% stake for $350 million. The block deal was structured with a floor price of ₹900.00 per share, representing a 6.9% discount to the stock's previous closing price.

Transaction Implications

The transaction comes with a 210-day lock-up period for further share sales, potentially stabilizing the stock in the short term. IIFL Capital served as the book-running lead manager for this significant market transaction.

Company Background

Cohance Lifesciences, formerly known as Suven Pharmaceuticals, is a contract development and manufacturing organisation (CDMO) catering to international pharmaceutical, biotech, and fine chemicals companies.

Stock Performance

Prior to this block deal, Cohance Lifesciences' shares had closed 2.5% lower at ₹965.50 in the previous trading session. The stock's recent performance has been mixed:

The execution of this large block deal and the subsequent stock price movement highlight the significant impact of institutional transactions on market dynamics. Investors and market watchers will likely keep a close eye on Cohance Lifesciences' stock performance in the coming days as the market absorbs this substantial change in ownership structure.